Twenty years or more can pass between a drug’s development and a Hatch-Waxman trial related to that drug. One key to a successful outcome against generic challengers in a Hatch-Waxman case is a compelling and factual invention story based on evidence that was created in real time—during the drug development and regulatory process.
Timing of Hatch-Waxman Litigation
The drug development process, by any standard, is very long. Although the exact timing varies considerably, clinical trials alone typically take six to seven years and that does not account for the drug discovery and preclinical testing work that must be done before clinical trials begin. From there, it can take several more years to go through the FDA review process before the drug can enter the market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]